- At ASCO, Merck makes case for a ‘cornerstone’ cancer drug<p>Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.</p>BioPharma Dive · 1mo ago↗ source
- Bristol Myers unveils data for one of its next-gen blood cancer drugs<figure><div><img src="https://imgproxy.divecdn.com/aUhcesS0eCO3NThNNqPfIC_gM2-0lSalzL7WEg-RP7g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02ODA4MDQ3ODAuanBn.…BioPharma Dive · 1mo ago↗ source
- STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchersThe Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.